CJC-1295 vs Sermorelin — GHRH Analog Comparison
Both CJC-1295 and sermorelin are GHRH analogs that stimulate the pituitary via the GHRH receptor, but they differ in structure, half-life, and market positioning. Sermorelin is a 29-amino-acid fragment matching the active region of natural GHRH, while CJC-1295 is a modified synthetic analog designed for extended circulation. Neither is FDA-approved for general use, though sermorelin was previously marketed as a diagnostic agent.
Mechanism Comparison
| Property | CJC-1295 (GHRH Analog) | Sermorelin (GHRH 1-29) |
|---|---|---|
| Receptor target | GHRH receptor | GHRH receptor |
| Structure | Modified synthetic GHRH analog (30 amino acids) | GHRH 1-29 fragment (29 amino acids) |
| Half-life | ~30 min (no-DAC) to 6–8 days (with DAC) | ~10–20 minutes |
| FDA history | None identified | Previously approved as Geref (diagnostic); now discontinued |
| Release pattern | Sustained (DAC) or short-pulse (no-DAC) | Short, pulsatile — mimics endogenous release |
| Key distinction | Modified structure for longer circulating half-life | Closest to native GHRH fragment biology |
Evidence Maturity
| Dimension | CJC-1295 (GHRH Analog) | Sermorelin (GHRH 1-29) |
|---|---|---|
| Clinical history | No clinical trial registry entries found | Decades of published GHRH research on the 1-29 fragment |
| Preclinical depth | Limited published characterization of the modified analog | Well-documented in endocrinology literature |
| Research-vendor prevalence | Commonly available (both DAC and no-DAC forms) | One of the most widely stocked research peptides |
Regulatory Status
CJC-1295 holds no FDA approval for any indication. Sermorelin was previously FDA-approved under the brand name Geref as a diagnostic tool but has since been discontinued commercially. Research-market versions of both are sold as chemicals for laboratory study only. The FDA has issued guidance on unapproved peptide products.
Quality and COA Checklist
- Third-party COA: Both compounds should have batch-linked certificates from independent laboratories
- Purity ≥98%: HPLC/MS data should be visible — not just a stated percentage
- Research-use-only labeling: Vendors should not provide dosing, injection, or human-use guidance
- Transparent payment: Legitimate vendors have clear business payment methods and refund policies
- Source dating: COAs should be within the last 6–12 months for current inventory
Frequently Asked Questions
Are CJC-1295 and sermorelin the same?
No. While both act on the GHRH receptor, sermorelin is the 29-amino-acid active fragment of natural GHRH, whereas CJC-1295 is a modified synthetic analog designed for extended half-life. They are similar in mechanism but different in structure and pharmacokinetics.
Which one has been studied more?
Sermorelin (GHRH 1-29) has a much longer research history with published studies in clinical endocrinology. CJC-1295 is a newer synthetic analog with less published independent characterization.
What is DAC in CJC-1295?
DAC (Drug Affinity Complex) binds the peptide to albumin in circulation, dramatically extending its half-life from ~30 minutes to 6–8 days. Sermorelin has no equivalent modification and has a much shorter half-life.
Are either FDA-approved?
CJC-1295: no. Sermorelin: previously approved as Geref (diagnostic) but discontinued. Research-market versions of both are sold as chemicals only.
How do I verify vendor quality for these?
Request batch-linked third-party COAs with HPLC data for either compound. Reputable vendors should provide analytical data confirming ≥98% purity with chromatograms visible for independent review.
Related Pages
Peptide Vendor Rankings → · How to Read a COA → · Our Evaluation Methodology →
Verification Notes for CJC-1295 vs Sermorelin — GHRH Analog Comparison
This file is reviewed as part of the The Peptide Reviewer documentation system, which means the page is not judged by headline confidence alone. The desk checks whether the claim has a date, whether the source can be opened by a reader, whether commercial language is separated from editorial scoring, and whether a medical or regulatory boundary is visible before the reader reaches any vendor context.
For cjc 1295 vs sermorelin, the practical standard is source literacy. A reader should be able to trace the page back to primary records, compare those records with the current vendor or compound claim, and see what the page does not prove. If a vendor changes a COA, removes a lab report, edits a product page, or adds health-outcome language after this review date, the conclusion can change. That is why this publication keeps source dates, correction rules, and reviewer scope close to the article body instead of hiding them in a footer.
The editorial team uses the same baseline checks across peptide vendor reviews, compound explainers, comparison pages, trust pages, and author pages. First, the page must identify the entity or topic clearly. Second, it must point readers toward primary-source verification. Third, it must avoid personal-use instructions and medical recommendations. Fourth, it must disclose when affiliate economics could exist and state that payment does not change scoring, inclusion, risk labels, or rank order.
When the page discusses a compound, the review separates published research context from research-market product claims. Published studies, trial records, or regulatory documents can describe a molecule, but they do not verify a private vendor batch. When the page discusses a vendor, the review separates a vendor's public marketing from documentation that can be checked, including batch-linked certificates, lab identity, source dates, claims language, and correction history.
Readers should treat this file as an audit trail, not a shortcut. The safest way to use it is to open the listed sources, confirm the current date on the vendor or regulatory record, and compare that source with the page summary. If the source and summary disagree, the source wins until the page is corrected. If the source cannot be found, the claim should be treated as unverified.
This added review note also gives crawlers and readers the same context that the editors use internally: what kind of evidence matters, which trust pages govern the file, who owns the review boundary, and where a correction should start. That matters most on author, policy, and directory pages because those pages can look thin even when they carry important E-E-A-T signals. The added context makes the page auditable without turning it into a new article.
- PubMed for published biomedical literature and review context.
- ClinicalTrials.gov for registered trial status and study records.
- FDA for approval status, warning letters, labeling, and regulatory context.
Frequently Asked Questions
How should I verify this page?
Start with the date, then open the primary source rather than relying on a summary. For medical or regulatory context, check PubMed, ClinicalTrials.gov, and FDA records. For vendor context, check the live vendor page, the batch-linked COA, the named lab, and any archived claim record.
Does this page provide medical advice?
No. The Peptide Reviewer publishes editorial source checks and market-transparency reviews. It does not provide treatment advice, dosing protocols, cycles, stacks, injection instructions, reconstitution guidance, diagnosis help, or personal-use recommendations.
Can affiliate relationships change the conclusion?
No. Affiliate relationships, sponsored links, and referral economics do not change scoring, inclusion, rank position, risk labels, author attribution, or medical-review status. Any paid link must be disclosed before the link and marked with sponsored nofollow attributes.
What happens if a source changes?
The page should be updated through the corrections process. A new COA, a changed vendor claim, an FDA update, or a corrected trial record can change the page. Until that update is made, readers should trust the current primary source over the older summary.
Related Standards
Methodology → · Editorial Standards → · Medical Review Policy → · Corrections Policy → · Affiliate Disclosure →